Long Term Follow-up Study for rAAv-GAD Treated Subjects.
Phase of Trial: Phase III
Latest Information Update: 21 Feb 2012
At a glance
- Drugs NLX P101 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 21 Feb 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 02 Mar 2011 New trial record